Hubify (ASX:HFY) grows its EBITDA by over 300%
Nick Sundich, July 18, 2023
ICT and cybersecurity services provider Hubify (ASX:HFY) impressed its shareholders with a trading update on Tuesday morning. Unaudited results depict record revenues and EBITDA more than quadrupling!
SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER NOW!
Hubify appears to have had a strong FY23
Hubify has released unaudited results for FY23. The company’s revenues from customers only increased by 8% but it nonetheless recorded a record with $25.7m.
EBITDA was only $1m but appears to be $4.4m in FY23, representing 342% growth! Cash at bank more than doubled from $2.7m to $5.6m and the company retains its debt-free status. The company credited the result to the continued take-up of managed and professional services as well as generating synergies from past acquisitions.
Good growth expected in FY24
Hubify told investors that it expected a good year in FY24. If reported the expansion of enterprise customer offerings in business IT, Cloud services, IT infrastructure and cybersecurity as well as strong customer demand for both. It also hinted at further M&A activity in the months ahead.
Stocks Down Under Concierge is here to help you pick winning stocks!
The team at Stocks Down Under have been in the markets since the mid-90s and we have gone through many ups and downs. We have written about every sector!
Our Concierge BUY and SELL service picks the best stocks on ASX. We won’t just tell you what to buy – we give you a buy range, price target and stop loss level in order to maximise total returns. And we will only recommend very high conviction stocks where substantial due diligence has been conducted.
Our performance is well ahead of the ASX200 and All Ords.
You can try out Concierge for 3 months … for FREE.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017
Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…
CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know
In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…